Request Demo
Last update 04 Aug 2025
Nicergoline
Last update 04 Aug 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms (8β)-10-methoxy-1,6-dimethylergoline-8-methanol 5-bromo-3-pyridinecarboxylate (ester), 10-methoxy-1,6-dimethylergoline-8β-methanol 5-bromonicotinate, Nicergo1ine + [10] |
Target |
Action antagonists |
Mechanism ADRA1 antagonists(Adrenergic receptor alpha-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date South Korea (16 Dec 1978), |
Regulation- |
Login to view timeline
Structure/Sequence
Molecular FormulaC24H26BrN3O3 |
InChIKeyYSEXMKHXIOCEJA-FVFQAYNVSA-N |
CAS Registry27848-84-6 |
Related
32
Clinical Trials associated with NicergolineCTR20241708
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的随机、开放、单剂量、四周期、完全重复交叉设计的生物等效性试验
[Translation] A randomized, open-label, single-dose, four-period, completely repeated crossover bioequivalence study of a single oral dose of nicergoline tablets in healthy adult subjects in the fasting and fed state
CTR20234046
健康受试者餐后状态下单次口服尼麦角林片的生物等效性试验
[Translation] Bioequivalence study of a single oral dose of nicergoline tablets in healthy volunteers in the fed state
CTR20233222
健康成年受试者空腹和餐后状态下单次口服尼麦角林片的生物等效性试验
[Translation] Bioequivalence study of a single oral dose of nicergoline tablets in healthy adult volunteers under fasting and fed conditions
100 Clinical Results associated with Nicergoline
Login to view more data
100 Translational Medicine associated with Nicergoline
Login to view more data
100 Patents (Medical) associated with Nicergoline
Login to view more data
817
Literatures (Medical) associated with Nicergoline27 Jun 2025Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Features of care of patients with cardiovascular diseases and cognitive disorders
Review
Author: Kochetkov, A.I. ; Ostroumova, O.D. ; Litvinova, S.V.
Due to the increase in life expectancy of the population, the proportion of people with cognitive impairment (CI) is also increasing. Today, it is known that cardiovascular diseases (CVD) are a significant risk factor for the development of CI. At the same time, the main substrate of CVD, including cerebrovascular events, is atherosclerosis. Statins are one of the most studied classes of drugs in the prevention of CVD. Atorvastatin (Liprimar) is one of the most studied and most frequently prescribed statins that has proven its effectiveness and safety in patients with a wide range of cardiovascular pathology. CI, in turn, lead to a decrease in functional autonomy, ability to work and adherence to treatment, thereby closing the vicious circle. Thus, therapy for CI should be initiated as early as possible, since they are a progressive disorder that eventually transforms into dementia. One of the drugs that has been used for 50 years for symptomatic therapy of CI, including dementia, chronic cerebrovascular and organic brain damage, is nicergoline (Sermion).
01 Apr 2025JOURNAL OF COLLOID AND INTERFACE SCIENCE
Low-frequency Raman spectroscopy as a new tool for understanding the behaviour of ionisable compounds in dispersed mesophases
Article
Author: Krog, Lasse S ; Boyd, Ben J ; Kihara, Shinji ; Mota-Santiago, Pablo ; Foderà, Vito ; Bērziņš, Kārlis
HYPOTHESIS:
Low-frequency Raman (LFR) spectroscopy is proposed as a novel non-destructive methodology to probe pH-related phase transitions in self-assembled lipid particles. In this case, dispersed lipid mesophases were composed of ionisable oleic acid (OA) or nicergoline (NG) in monoolein (MO). The sensitivity of LFR spectroscopy to low-energy intermolecular vibrations was hypothesised to be due to structural transformation in ionisable dispersed mesophases upon changes in pH.
METHOD/EXPERIMENT:
Phase transitions of dispersed mesophases of MO mixed with OA or NG were induced by varying the pH of the aqueous buffer. The structural transformations were studied using LFR spectroscopy, recording the corresponding changes in the vibrational density of states (VDOS) upon changes in pH and analysed using principal component analysis (PCA). The results were correlated with structural transitions observed in simultaneous small-angle X-ray scattering (SAXS) measurements.
FINDINGS:
The intensity of the VDOS signal of MO + OA mesophases scaled with phase-specific transformations, such as from the bi-continuous cubic Im3¯m phase (V2) or lamellar-based vesicles to the reversed hexagonal p6m phase (H2). For NG subtle changes in the lattice parameter of the V2 phase of NG + MO mesophases coincided with the apparent dissociation constant (pKaapp) of NG, however, slight variations between the pKaapp of NG determined by equilibrated samples analysed using SAXS and non-equilibrated samples analysed using LFR suggest structural hysteresis upon changes in the protonation state of NG. This approach offers an efficient method for studying the phase behaviour of lipid systems under varying pH and potentially other conditions such as temperature.
01 Jan 2025Therapeutic Advances in Neurological Disorders
Drug-induced dementia: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
Article
Author: Xu, Lisi ; Zhang, Ruonan ; Zhang, Xiaolin ; Shang, Xiuli ; Huang, Daifa
Background::
Dementia is a serious adverse event (AE) that requires attention in clinical practice. However, information on drug-induced dementia is limited. The U.S. FDA Adverse Event Reporting System (FAERS) serves as an important resource for identifying real-world adverse drug reactions and safety signals.
Objective::
This study aimed to use FAERS data to identify drugs associated with increased dementia risk.
Design::
A secondary analysis of the FAERS database was conducted using disproportionality analysis methods.
Methods::
We reviewed dementia-related reports in the FAERS database from the first quarter of 2004 to the fourth quarter of 2023, used the Medical Dictionary for Regulatory Activity to identify dementia cases and summarized the corresponding list of potential medications, counted the dementia-causing medication classes with the highest frequency of reports, and disaggregated all medications.
Results::
The study identified 31,881 dementia-related AEs in the FAERS database, with an increasing trend over time, particularly among females and individuals over 65. Apixaban had the most reports (1631). Disproportionality analyses revealed that rivastigmine, nicergoline, aducanumab, amlodipine/atorvastatin, and dihydroergometrine had the highest risk, based on reporting odds ratio, proportional reporting ratio, and information component. Only valproate and tramadol among the top 50 drugs included a potential dementia risk in their package inserts.
Conclusion::
This study identified a list of medications associated with dementia risk, many of which lack dementia warnings on their labels. Increased monitoring is necessary for high-risk individuals, and further research is required to clarify these associations and improve patient safety.
1
News (Medical) associated with Nicergoline
100 Deals associated with Nicergoline
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D01290 | Nicergoline |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Dizziness | China | 15 Dec 2000 | |
| Intellectual Disability | China | 15 Dec 2000 | |
| Mood Disorders | China | 17 Sep 1999 | |
| Peripheral Vascular Diseases | China | 17 Sep 1999 | |
| Arteriosclerosis | South Korea | 16 Dec 1978 | |
| Brain Infarction | South Korea | 16 Dec 1978 | |
| Dementia | South Korea | 16 Dec 1978 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Phase 3 | United States | - | |
| Affective Disorders, Psychotic | Phase 1 | China | 30 Apr 2020 | |
| Dementia, Vascular | Phase 1 | China | 30 Apr 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free